Simplify Logo
CSL

CSL

Develops and delivers biotherapies and vaccines

Associate Director, Research Biostatistics

Full-Time
No salary listed
Senior, Expert
PhD
Waltham, MA, USA
In Person

About the job

Requirements
  • PhD in Statistics, Biostatistics, or equivalent experience.
  • At least 8 years of experience applying statistics in a pre-clinical pharmaceutical, biotechnology, healthcare, or biomedical research environment, supporting discovery, translational, biomarker, or early development programs.
  • Demonstrated experience developing and applying advanced statistical methodologies for biological, translational, biomarker, omics, imaging, or related scientific data.
  • Proven experience with modern statistical programming, reproducible analysis workflows, and quantitative computing platforms, particularly R and related technologies.
  • Evidence of scientific contribution through publications, conference presentations, methodological innovations, or development of analytical tools and platforms.
Responsibilities
  • Provide strategic statistical leadership and methodological oversight across discovery, translational, and early research programs, ensuring robust study design, analysis, interpretation, and project decision support.
  • Lead and perform complex statistical analyses across preclinical, translational, biomarker, imaging, omics, and human research datasets using advanced methodologies such as Bayesian methods, causal inference, longitudinal modelling, and machine learning.
  • Develop and apply innovative statistical methods, reproducible analytical workflows, and statistical programming solutions, particularly in R and related platforms.
  • Support biomarker identification, evaluation, and validation activities, contributing to translational evidence-generation strategies that strengthen research and portfolio decisions.
  • Translate complex scientific data into actionable insights that support target evaluation, candidate selection, project progression, portfolio prioritisation, and probability-of-success assessments.
  • Collaborate with Translational Bioinformatics, Global Biometrics, Data Management, PK/PD, and other quantitative functions, applying state-of-the-art statistical methodologies to address scientific challenges.
  • Contribute to scientific publications, ethics submissions, external collaborations, and scientific communications.
  • Mentor and develop statisticians, scientists, contractors, and interns, providing scientific leadership and fostering continuous learning.
  • Champion data-driven decision making, promote statistical best practices, and deliver training to strengthen analytical capability across the organisation.
  • Establish and manage relationships with external collaborators, academic partners, CROs, consultants, and technology providers, ensuring delivery of high-quality scientific outcomes.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL realized US$176 million FY26 cost savings, above target, improving margins.
  • September 10, 2026 Lancet data strengthens AUJEMFLU's case with older adults and regulators.
  • CSL's VarmX collaboration funds Phase 3 VMX-C001, expanding into urgent-surgery anticoagulation reversal.

What critics are saying

  • FY26 reported a US$2.6 billion loss after US$7.1 billion impairments and restructuring.
  • Pentagon's April 2026 flu mandate repeal cuts Seqirus demand from a major buyer.
  • CSL reported March 2026 temporary global HEMGENIX availability issues, risking treatment continuity and trust.

What makes CSL unique

  • CSL's FY26 portfolio spans plasma, gene therapy, and leading influenza vaccines.
  • HEMGENIX posted 25% FY26 growth, sustaining durable haemophilia B demand.
  • AUJEMFLU won MHRA and European Commission approval, plus Lancet superiority data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.

Yahoo Finance
Aug 17th, 2026
CSL reports 2% drop in annual profit to $3.14B on weak plasma sales

Australian biopharmaceutical company CSL reported a 2% decline in annual profit on Tuesday, as its core plasma division experienced falling revenue. The company posted an underlying net profit after tax of $3.14 billion on a constant currency basis for the year ended 30 June, down from $3.22 billion the previous year. CSL is among the world's leading flu vaccine manufacturers. The results reflect challenges in the plasma business, which forms a significant part of the company's operations.

Yahoo Finance
May 2nd, 2026
CSL to split Seqirus vaccine unit as shares slide 50% amid restructure and cost cuts

CSL has announced a restructuring plan including the separation of its Seqirus influenza vaccine business into a standalone entity, alongside workforce reductions and plasma collection centre closures. Management cited prolonged margin pressures and operational challenges as drivers for the changes. The announcement follows a sharp share price decline, with CSL trading at A$124.84, down 27.4% year-to-date and 50.1% over the past year. Three-year and five-year returns show declines of 56.3% and 51.0% respectively. The restructuring aims to simplify operations and refocus capital on higher-returning areas. Separating Seqirus could provide clearer visibility into CSL's core plasma and specialty therapies businesses, whilst allowing independent capital allocation decisions. However, investors face execution risks typical of separations of this scale, including one-off charges and operational disruption.

Yahoo Finance
Apr 23rd, 2026
CSL shares hit 2017 low as Pentagon scraps flu vaccine mandate for military personnel

Australian biotech CSL extended losses on Thursday, falling to its lowest level since August 2017, after the US Pentagon scrapped its flu vaccine mandate for military personnel. The stock dropped as much as 0.8%, bringing yearly losses to over 25%. The policy reversal threatens demand from a key institutional buyer, compounding CSL's existing challenges. The company's Seqirus vaccines unit generated $2.17 billion in revenue in fiscal 2025, representing 14% of total revenue. CSL has faced sustained pressure from slowing demand for plasma-derived therapies, higher costs and multiple earnings downgrades. The stock plunged 39% last year, its biggest annual drop since 2002. Analysts cite concerns over falling US flu vaccination rates, weaker Seqirus earnings and delayed strategic plans.

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.